Skip to Main content Skip to Navigation
New interface
Journal articles

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer

Abstract : Lung cancer is the leading cause of cancer-related deaths among men and women worldwide. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective therapies for advanced non-small-cell lung cancer (NSCLC) patients harbouring EGFR-activating mutations, but are not curative due to the inevitable emergence of resistances. Recent in vitro studies suggest that resistance to EGFR-TKI may arise from a small population of drug-tolerant persister cells (DTP) through non-genetic reprogramming, by entering a reversible slow-to-non-proliferative state, before developing genetically derived resistances. Deciphering the molecular mechanisms governing the dynamics of the drug-tolerant state is therefore a priority to provide sustainable therapeutic solutions for patients. An increasing number of molecular mechanisms underlying DTP survival are being described, such as chromatin and epigenetic remodelling, the reactivation of anti-apoptotic/survival pathways, metabolic reprogramming, and interactions with their micro-environment. Here, we review and discuss the existing proposed mechanisms involved in the DTP state. We describe their biological features, molecular mechanisms of tolerance, and the therapeutic strategies that are tested to target the DTP.
Complete list of metadata
Contributor : Olivier Calvayrac Connect in order to contact the contributor
Submitted on : Wednesday, October 19, 2022 - 9:44:57 AM
Last modification on : Wednesday, November 23, 2022 - 12:02:33 PM


Publisher files allowed on an open archive




Celia Delahaye, Sarah Figarol, Anne Pradines, Gilles Favre, Julien Mazieres, et al.. Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer. Cancers, 2022, 14 (11), pp.2613. ⟨10.3390/cancers14112613⟩. ⟨hal-03820489⟩



Record views


Files downloads